Lower Total Adipocyte Number but No Evidence for Small Adipocyte Depletion in Patients With Type 2 Diabetes by Pasarica, Magdalena et al.
Lower Total Adipocyte Number but No
Evidence for Small Adipocyte Depletion in
Patients With Type 2 Diabetes
MAGDALENA PASARICA, MD, PHD
HUI XIE, MS
DAVID HYMEL, MS
GEORGE BRAY, MD
FRANK GREENWAY, MD
ERIC RAVUSSIN, PHD
STEVEN R. SMITH, MD
OBJECTIVE — We hypothesized that, compared with obese subjects, patients with type 2
diabetes have a lower total adipocyte number with fewer small adipocytes.
RESEARCHDESIGNANDMETHODS — Abdominalsubcutaneousadiposetissuewas
obtained from lean and obese subjects with or without type 2 diabetes matched for BMI.
Adipocyte size was measured by osmium ﬁxation and sizing/counting in a Coulter counter.
Adipocyte size and number subdistributions (small, medium, large, and very large) were
determined.
RESULTS — Compared with obese subjects, type 2 diabetic patients had larger mean adipo-
cyte size and 67% bigger very large adipocytes; the total adipocyte number was lower, but the
fraction of small adipocytes was increased by 27%.
CONCLUSIONS — Total adipocyte cellularity is lower in type 2 diabetic subjects than in
obese subjects. We found no evidence for depletion of small adipocytes in patients with type 2
diabetes.Thissuggeststhepresenceofadefectinearlymaturationofadipocytesinpatientswith
type 2 diabetes.
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T
here is a growing appreciation that
adipose tissue dysfunction in type 2
diabetes is due in part to adipocyte
hypertrophia. Mean adipocyte size is in-
versely correlated with insulin sensitivity
(1). A greater number of small adipocytes
isassociatedwithinsulinsensitivity(2,3).
Danforth (4) hypothesized that adipo-
cytes are hypertrophic due to defects in
preadipocyte differentiation to adipo-
cytes, leading to an inability to buffer ex-
cess dietary fat.
Inthisstudy,weaimedtoidentifythe
differences in adipocyte size and number
subdistributions in abdominal subcuta-
neous adipose tissue (SAT) of lean and
obese subjects with or without type 2 di-
abetes. We hypothesized that, compared
with obese subjects, type 2 diabetic pa-
tients have a lower total adipocyte num-
ber with fewer small adipocytes.
RESEARCH DESIGN AND
METHODS— The present study used
baseline data collected from 260 patients
participatinginavarietyofclinicalstudies
at the Pennington Biomedical Research
Center.Patientswereexcludediftheyhad
signiﬁcant renal, cardiac, liver, lung, or
neurological disease. Hypertension was
acceptable if blood pressure was less than
140/90 mmHg on medications. Patients
were excluded for prior use of thiazo-
lidinediones or drugs known to affect
lipid metabolism, energy metabolism, or
body weight or drug abuse and smoking.
The study included three groups: lean
(BMI 25 kg/m
2), obese (BMI 25 kg/
m
2), and obese with type 2 diabetes (BMI
25 kg/m
2). Protocols were approved by
the Institutional Review Board of the
Pennington Biomedical Research Center.
All volunteers gave written informed
consent.
Body fat mass was measured by dual-
energy X-ray absorptiometry. Visceral
and subcutaneous fat mass was measured
usingaGEHigh-SpeedCTscanner.From
the eight cross-sectional areas, visceral
adipose tissue (VAT) volume was calcu-
lated and converted to VAT mass (kilo-
grams) using the conversion factor
0.9193 kg/l for adipose tissue.
Thehomeostasismodelassessmentof
insulin resistance (HOMA-IR) index was
calculated by multiplying the fasting glu-
coselevel(millimolesperliter)bythefast-
inginsulinlevel(microunitspermilliliter)
and dividing the product by 22.5 (5).
Adipocytesizingwasperformedaspre-
viously described (2). Brieﬂy, abdominal
SAT samples were ﬁxed in osmium tetrox-
ide and digested with 8 mol/l urea in 154
mol/lNaClsolution.Cellswereﬁlteredover
a1 0m nylon screen, collected into a Tri-
ton X-100 solution, and analyzed on a
Coulter counter. The diameter of each os-
mium-ﬁxedtriglyceridedropletwasusedto
calculate cell volume. Using statistical anal-
ysis (details can be found in an online ap-
pendix, available at http://care.diabetes
journals.org/cgi/content/full/dc08-2240/
DC1),fouradipocytesubdistributionswere
identiﬁed as follows: small, medium, large,
andverylarge.Thismethodishighlyrepro-
ducible (R
20.785) (supplemental Figure
A3).Thesubdistributionfractionistheper-
centageofadipocytesinaspeciﬁcsubdistri-
bution. Adipocyte number was determined
bydividingthesubcutaneousabdominalfat
mass(multislicecomputedtomography)by
theabdominalsubcutaneousmeansize(6).
Comparison between lean, obese, and
type 2 diabetic subjects was performed
usinganANCOVAtestwithsex,race,and
age as covariates. Statistical signiﬁcance is
deﬁned relative to a nominal two-sided
5% type 1 error rate. Tukey-Kramer ad-
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hoc test.
RESULTS— The obese and type 2 di-
abetic patients were matched for BMI and
abdominal SAT; however, the latter had
more VAT. The characteristics of the
study populations are presented in sup-
plemental Table 1.
Mean  SD adipocyte size was larger
in patients with type 2 diabetes than in
obese subjects (1.0  0.05 vs. 0.79 
0.04 l; P  0.05). Compared with BMI-
matched obese subjects, patients with
type 2 diabetes had 67% bigger very large
adipocytes and 20% smaller small adipo-
cyte size (Fig. 1A). Importantly, total adi-
pocytenumberwaslowerinpatientswith
type 2 diabetes (P  0.05) while the frac-
tion of small adipocytes was 27% greater
(P  0.05) (Fig. 1B and supplemental
Table 2).
In lean and obese subjects, BMI was
positively correlated with adipocyte mean
size, large size, and very large size (R 
0.57, R  0.36, and R  0.25, respec-
tively; P  0.05) and negatively with
small adipocyte size (R  0.39; P 
0.05). HOMA-IR, a marker of insulin re-
sistance, was positively correlated with
adipocyte mean size, large size, and very
large size (R  0.54, R  0.27, and R 
0.41, respectively; P  0.05) and nega-
tively with small size (R  0.35; P 
0.05). Adipocyte number was positively
correlatedwithHOMA-IR(R0.32;P
0.05).
There are no signiﬁcant correlations
between adipocyte size and number with
BMI in patients with type 2 diabetes.
CONCLUSIONS — In this large sam-
ple of adipose tissue biopsies, we show
for the ﬁrst time that patients with type
2diabeteshavefewersubcutaneousadi-
pocytes compared with BMI-matched
obese subjects. This suggests that in in-
dividualswithtype2diabetes,thenum-
ber of adipocytes fails to increase as
body fat increases. As suggested by
Danforth, this may lead to fat accumu-
lation in tissues such as VAT, muscle,
and liver—all known to contribute to
insulin resistance. We found that pa-
tients with type 2 diabetes have in-
creased visceral tissue, supporting the
concept that a failure of SAT to store
energy leads to an increase in VAT and
possibly other sites of ectopic fat. How-
ever, it is possible that these individuals
have a low number of adipocytes in
childhood; consequently, if this num-
ber is ﬁxed, as some studies suggest,
they might be at risk for developing di-
abetes as adults.
ComparedwithBMI-matchedobese
subjects, patients with type 2 diabetes
had greater mean adipocyte size mainly
driven by an increased size of the very
large adipocyte, suggesting that type 2
diabetes is accompanied by hypertro-
phia rather than hyperplastia. Contrary
to our hypothesis, patients with type 2
diabetes have greater fraction of small
adipocytes. The increased size of the
largestadipocyte(verylarge)inpatients
with type 2 diabetes might stimulate re-
cruitmentandproliferationofanadipo-
cyte precursor, which leads to greater
small adipocytes fraction (7). However,
the size of small adipocytes is lower,
suggesting that these new adipocytes
cannot further accumulate lipid.
These observations suggest impair-
ment of the complete maturation of adi-
pocytes with no effect on late fatty acid
Figure 1—Adipocyte subdistributions (size and number) in lean, obese, and type 2 diabetic subjects. Abdominal SAT samples were ﬁxed,
digested, and analyzed on a Coulter counter. The diameter of each osmium-ﬁxed triglyceride droplet was used to calculate cell volume. For
each participant, four subdistributions were determined: small (S), medium (M), large (L), and very large (VL) adipocytes. There were 27
participants in the lean group, 192 in the obese group, and 41 with type 2 diabetes. Comparison was performed using ANCOVA tests with sex,
race, and age as covariates. Tukey-Kramer adjustment (  0.05) was used as a post hoc test. A: There is no signiﬁcant difference in small,
medium, large, and very large adipocyte size subdistribution in obese compared with lean patients. Interestingly, compared with the
BMI-matched obese subjects, patients with type 2 diabetes have smaller small and medium adipocytes and bigger very large adipocytes. Data
are means  SD. *P  0.05. B: Adipocyte number was determined by dividing the subcutaneous abdominal fat mass by the adipocyte mean
size. Each subdistribution fraction represents percentage of adipocytes in a speciﬁc subdistribution from the total number of adipocytes
analyzed. Boxes represent the mean of each subdistribution absolute number. Means  SD of the adipocyte fractions expressed as percentage
fromthetotaladipocytenumberarepresentedinsupplementalTable2.Totaladipocytenumberissmallestinleanandbiggerinobesepatients
and those with 2 diabetes (P  0.05). Interestingly, patients with type 2 diabetes have less adipocytes than BMI-matched obese subjects
(P  0.05).However,fromallthesubdistributions,thesmallfraction(percentfromthetotaladipocytenumber[%])wassigniﬁcantlygreater
in patients with type 2 diabetes than in BMI-matched obese subjects (P  0.05).
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This hypothesis is in accordance with
recent data showing that insulin resis-
tance per se causes impairment in adi-
pogenesis (8,9). Future studies should
test this novel hypothesis, i.e., that
there might be a defect in the complete
maturation of small adipocytes in pa-
tients with type 2 diabetes (supplemen-
tal Figure 4).
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